| A 45-amino-acid scaffold mined from the PDB for high-affinity ligand engineering MA Kruziki, S Bhatnagar, DR Woldring, VT Duong, BJ Hackel Chemistry & biology 22 (7), 946-956, 2015 | 69 | 2015 |
| Quantitative systems pharmacology approaches for immuno‐oncology: adding virtual patients to the development paradigm V Chelliah, G Lazarou, S Bhatnagar, JP Gibbs, M Nijsen, A Ray, B Stoll, ... Clinical Pharmacology & Therapeutics 109 (3), 605-618, 2021 | 59 | 2021 |
| Computational transport analysis of antibody-drug conjugate bystander effects and payload tumoral distribution: implications for therapy E Khera, C Cilliers, S Bhatnagar, GM Thurber Molecular Systems Design & Engineering 3 (1), 73-88, 2018 | 51 | 2018 |
| Mechanistic and quantitative insight into cell surface targeted molecular imaging agent design L Zhang, S Bhatnagar, E Deschenes, GM Thurber Scientific reports 6 (1), 25424, 2016 | 40 | 2016 |
| Multichannel imaging to quantify four classes of pharmacokinetic distribution in tumors S Bhatnagar, E Deschenes, J Liao, C Cilliers, GM Thurber Journal of pharmaceutical sciences 103 (10), 3276-3286, 2014 | 32 | 2014 |
| Oral and subcutaneous administration of a near-infrared fluorescent molecular imaging agent detects inflammation in a mouse model of rheumatoid arthritis S Bhatnagar, E Khera, J Liao, V Eniola, Y Hu, DE Smith, GM Thurber Scientific reports 9 (1), 4661, 2019 | 28 | 2019 |
| Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug–drug interaction predictions using a PBPK approach S Bhatnagar, D Mukherjee, AH Salem, D Miles, RM Menon, JP Gibbs Cancer Chemotherapy and Pharmacology 87, 465-474, 2021 | 25 | 2021 |
| Oral administration and detection of a near-infrared molecular imaging agent in an orthotopic mouse model for breast cancer screening S Bhatnagar, KD Verma, Y Hu, E Khera, A Priluck, DE Smith, GM Thurber Molecular pharmaceutics 15 (5), 1746-1754, 2018 | 24 | 2018 |
| Fractal impeller for stirred tank reactors AA Kulkarni, N Jha, A Singh, S Bhatnagar, BD Kulkarni Industrial & engineering chemistry research 50 (12), 7667-7676, 2011 | 21 | 2011 |
| Mechanistic modeling of intra‐tumor spatial distribution of antibody‐drug conjugates: insights into dosing strategies in oncology J Weddell, MS Chiney, S Bhatnagar, JP Gibbs, M Shebley Clinical and translational science 14 (1), 395-404, 2021 | 13 | 2021 |
| Upadacitinib: Mechanism of action, clinical, and translational science MEF Mohamed, S Bhatnagar, JM Parmentier, P Nakasato, P Wung Clinical and Translational Science 17 (1), e13688, 2024 | 12 | 2024 |
| Population Pharmacokinetic and Exposure–Response Analyses for Efficacy and Safety of Risankizumab in Patients With Active Crohn's Disease AA Suleiman, A Goebel, S Bhatnagar, R D'Cunha, W Liu, Y Pang Clinical Pharmacology & Therapeutics 113 (4), 839-850, 2023 | 9 | 2023 |
| Population pharmacokinetics and exposure‐response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritis S Bhatnagar, D Eckert, S Stodtmann, IH Song, P Wung, W Liu, ... Clinical and Translational Science 17 (2), e13733, 2024 | | 2024 |
| POS1137 PHARMACOKINETICS AND EXPOSURE-RESPONSE RELATIONSHIPS OF UPADACITINIB OR ELSUBRUTINIB ALONE OR IN COMBINATION (ABBV-599) IN SYSTEMIC LUPUS ERYTHEMATOUS S Bhatnagar, L Siovitz, A Friedman, W Liu, ME Mohamed Annals of the Rheumatic Diseases 82 (Suppl 1), 896-897, 2023 | | 2023 |
| Tu1733 UPADACITINIB PHARMACOKINETIC AND EXPOSURE-RESPONSE RELATIONSHIPS IN SUBJECTS WITH CROHN'S DISEASE-ANALYSES OF PHASE 3 STUDIES S Bhatnagar, L Schlacter, D Eckert, S Stodtmann, W Liu, AP Lacerda, ... Gastroenterology 164 (6), S-1100-S-1101, 2023 | | 2023 |
| Upadacitinib Pharmacokinetics and Exposure-Response Relationships for Efficacy and Safety in Axial Spondyloarthritis-Analyses of the Phase 3 Studies (SELECT-AXIS 1 and 2) S Bhatnagar, D Eckert, S Stodtmann, IH Song, P Wung, W Liu, ... ARTHRITIS & RHEUMATOLOGY 74, 850-851, 2022 | | 2022 |
| Evaluating Engagement of ABBV-0805, an Anti-Alpha-Synuclein Monoclonal Antibody to Physiological and Pathological Forms of Alpha-Synuclein for Phase 2 Dose Selection: A PBPK … H Kalluri, S Bhatnagar, L Rueter, C Zadikoff, O Graff, P Noertersheuser, ... MOVEMENT DISORDERS 36, S179-S179, 2021 | | 2021 |
| Protein scaffolds and methods of use BJ Hackel, MA Kruziki, S Bhatnagar, H Zhou US Patent 10,287,572, 2019 | | 2019 |
| MECHANISTIC MODELING TO UNDERSTAND INTRA-TUMOR SPATIAL DISTRIBUTION OF ANTIBODY DRUG CONJUGATES: INSIGHTS INTO DOSING STRATEGY IN ONCOLOGY. M Chiney, S Bhatnagar, J Weddell, JP Gibbs, M Shebley CLINICAL PHARMACOLOGY & THERAPEUTICS 103, S27-S28, 2018 | | 2018 |
| Orally Available Near Infrared Imaging Agents for the Early Detection of Diseases S Bhatnagar | | 2018 |
